Lamivudine treatment in maternally transmitted chronic hepatitis B virus infection patients

Yen Hsuan Ni, Fu Chen Huang, Tzee Chung Wu, Man Shan Kong, Yung Ming Jeng, Pei Jer Chen, Daw Jen Tsuei, Huey Ling Chen, Hong Yuan Hsu, Mei Hwei Chang*

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

18 Scopus citations


Background: Lamivudine treatment in chronic carriers who acquired hepatitis B virus through maternal transmission were investigated. Methods: A total of 29 subjects (Male: Female, 24:5; mean age, 14.7 ± 5.6 years) who were hepatitis B e antigen (HBeAg) seropositive for >6 months, alanine aminotransferase (ALT) was >1.3 times of upper limit of normal value, and receiving a 52 week-long treatment, received open-label lamivudine (3 mg/kg per day, maximum 100 mg/day). Another 29 subjects matched for gender, age, liver function, and HBeAg status followed up before the introduction of lamivudine served as the control group. The control group did not receive any treatment and were evaluated at week 52 after the onset of abnormal ALT. Mothers of all study subjects were hepatitis B surface antigen (HBsAg) carriers. A successful treatment response at week 52 was defined as: (i) undetectable hepatitis B virus DNA by real time polymerase chain reaction; (ii) normal ALT; and (iii) HBeAg/anti-HBe seroconversion. Lamivudine-resistant YMDD mutants were checked at week 52. Results: The lamivudine group did not reach a better successful treatment response rate than the control group (17 vs 10%, P = 0.44), except in patients with a baseline ALT >5 times of the upper limit of normal value. YMDD mutants developed in 34% of patients in the lamivudine group. Conclusion: Lamivudine treatment is effective for maternally transmitted subjects with high ALT.

Original languageEnglish
Pages (from-to)372-377
Number of pages6
JournalPediatrics International
Issue number4
StatePublished - 08 2005
Externally publishedYes


  • B virus
  • Hepatitis
  • Lamivudine
  • Maternal transmission
  • Real time polymerase chain reaction
  • YMDD mutant


Dive into the research topics of 'Lamivudine treatment in maternally transmitted chronic hepatitis B virus infection patients'. Together they form a unique fingerprint.

Cite this